According to the news from the website of the Drug Evaluation Center of the State Drug Administration, the first-in-class hepatitis B new drug Hepalatide developed by Shanghai Hepu Pharmaceutical Co., Ltd. has obtained the default license of NMPA clinical trials and will Phase II / III clinical development stage.

The new version of the website of Shanghai Hepu Pharmaceutical Co., Ltd. is launched, becoming a platform for the company to interact with friends in the industry and hepatitis B patients, showing the latest progress of hepatitis B research and the development of our company's projects

On December 28, the "Technology Innovation Board" of the Shanghai Equity Custody Trading Center officially opened.

None of the more than 5,000 existing pharmaceutical companies in the country has entered the world's top 50 pharmaceutical companies. Even from the perspective of generic drugs, Chinese pharmaceutical companies are quite far away from generic drug giants such as Israel's Teva and Germany's Sandoz. "In a recent corporate interview, Dr. Liu Hongli, General Manager of Shanghai Hepu Biotechnology Co., Ltd., was worried about this.